期刊文献+

利拉鲁肽的临床药理作用及研究进展 被引量:11

下载PDF
导出
摘要 利拉鲁肽为一种人胰高糖素样肽-1(GLP-1)类似物,其在机体内的作用机制为通过对GLP-1受体起到激活作用,以促进胰岛素释放,同时对胰高血糖素的分泌起到抑制作用。大量研究证实,利拉鲁肽应用于老年2型糖尿病治疗可取得显著疗效,也可与其他口服降糖药物联用,从而达到更加突出的治疗效果,但不能应用于老年1型糖尿病的治疗。本文现针对利拉鲁肽的临床药理作用及应用作如下综述。
作者 董占玲
机构地区 海洋石油总医院
出处 《中国处方药》 2017年第3期10-11,共2页 Journal of China Prescription Drug
  • 相关文献

参考文献4

二级参考文献76

  • 1National Institutes of Health. National diabetes statistics 2007 Wprevalence of diagnosed and undiagnosed diabetes in the United States, all ages, 2007 [ EB/OL]. [2009 - 08 - 14]. http ://diabetes. niddk. nih. gov/dm/pubs/statistics/#allages.
  • 2RUSSELL-JONES D. Molecular,pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue[ J]. Mol Cell Endocrinol,2009,297 ( 12 ) : 137 - 140.
  • 3NAUCK MA, HEIMESAAT MM, BEHLE K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemie,stepped hypoglycemie clamp experiments in healthy volunteers[J]. J Clin Endocrinol Metab, 2002,87 (3) : 1239 - 1246.
  • 4ZINMAN B, GERICH J, BUSE JB,et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes(LEAD-4 Met + TZD ) [J]. Diabetes Care, 2009, 32 (7) : 1224 -1230.
  • 5BUSE JB, ROSENSTOCK J, SESTI G,et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial ( LEAD- 6)[J]. Lancet,2009,374(4): 39-47.
  • 6NAUCK M, MARRE M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits [ J ]. Postgrad Med, 2009,121(3): 5-15.
  • 7ASTRUP A, ROSSNER S, VAN GAAL L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind,placebo-controlled study [ J ]. Lancet, 2009, 374 ( 9701 ) : 1606 - 1616.
  • 8BOSE AK, MOCANU MM, CARR RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury[ J]. Diabetes,2005,54(1) :146 - 151.
  • 9MEECE J, FACA BS. Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glueagon-like peptide-1 analog [J]. Pharmacotherapy, 2009,29(12) :33S-42S.
  • 10CROOM KF, MCCORMACK PL. Liraglutide: A Review of its use in type 2 diabetes mellitus[J]. Drugs, 2009, 69(14): 1985 - 2004.

共引文献49

同被引文献137

引证文献11

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部